Vemurafenib
- Generic Name
- Vemurafenib
- Brand Names
- Zelboraf
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18ClF2N3O3S
- CAS Number
- 918504-65-1
- Unique Ingredient Identifier
- 207SMY3FQT
- Background
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...
- Indication
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...
- Associated Conditions
- Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
- Associated Therapies
- -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT03220035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
- Conditions
- Metastatic Thyroid Gland CarcinomaStage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8Poorly Differentiated Thyroid Gland CarcinomaStage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8Thyroid Gland Anaplastic CarcinomaUnresectable Thyroid Gland CarcinomaStage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03181100
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03178552
- Locations
- 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyDrug: Larotrectinib SulfateProcedure: Bone ScanProcedure: Mutation Carrier ScreeningOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: Selumetinib SulfateDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03139513
- Locations
- 🇫🇷
CH Metropole de Savoie, CHAMBERY Cedex, France
🇫🇷Hopital Louis Pasteur; Sce Dermatologie, Colmar, France
🇫🇷Hopital Cochin; Dermatologie, Paris, France
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03101254
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT03013491
- Locations
- 🇬🇧
PROCLAIM Invetigative Site, Glasgow, United Kingdom
🇬🇧PROCLAIM Investigative Site, Newcastle upon Tyne, United Kingdom
🇪🇸PROCLAIM Investigative Ssite, Valencia, Spain
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 514
- Registration Number
- NCT02908672
- Locations
- 🇺🇸
St. Luke's University Health network, Bethlehem, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
🇩🇪Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 186
- Registration Number
- NCT02902029
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Thuringia, Germany
🇩🇪Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, Germany
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Yana Najjar
- Target Recruit Count
- 9
- Registration Number
- NCT02818023
- Locations
- 🇺🇸
UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.